Member Info for Davemcmanus

Because he will pick snd chose thd questions he answers you muppet

Anyway it's Rememberance day, spend some thinking about those that have made sacrifises, served our country, that's afforded you the luxury to be on here rather than telling us how great Budd is.

Seems like this board has become relief board for VAL and NCYT holders to vent their frustrations.

Sunny thanks, as i said the other day all this stock needs is a bit of momentum behind it and it's off to the races. Woodford has already proven what the right momentum can do to this stock, and it's one area that the 4D management are lacking. They are far too quiet which doesn't help get the word out, hence inferior peers are trading at multiples our mcap, despite having BIG failures!!! 4D hasn't had a SINGLE failure to date, like you say too many external factors have influenced the SP here, but should see a steady rise from here on results. If it takes PIS to promote DDDD then so be it.

Crl123 we do not want to continously here your lifestories and whinging about losses on otger shares. Everyone knows the worst case scenario here, which is the platform fails and the SP goes to 0. However they have alot of upside with trial results, catching up NASDAQ peers etc...risk /ratio is favourable. NCYT got lucky with Covid testing which has died down considerably from peak, the SP suffered at a result. It was stupid retail that couldn't see the market would get more competitive, testing numbers woukd fall and revenue would decrease. There is no way it should have went to £12!! Hell it isn't even a Biotech like DDDD so your comparison was illogical anyway, comparing apples with oranges.

Also to add there has been dilution since then, from 64m shares to 180m but the company us much further in clinical progress.

Steve this share has never hit £1000, £10 was the maximum. That was because it had Woodford behind it, he was buying the stock and actively promoting or as some would say "pumping" it. This is effectively what gains recognition for a bio tech and put it into the radar of other specialist investors. There were a few reasons for the fall, and it has nothing to do with AIM. First of Seres announced a failure in one of their trials back in 2016, which meant the whole sector took a hit. They have announced another failure this Summer as have Forte, which again impacted 4D. The sharp drop last year was due to the Woodford fund getting into difficulty, having to sell down aggressively, which was reflected in all AIM bio stocks he held. This wasn't limited to 4D. None of the drops have been attributed to 4D's performance itself, which is a big positive.

And what's changed between now and April? Nothing expect news that was due here in the Summer has been delayed, so how does it make the broker note invalid?

Agreed

Sang i agree, i was being conservative before i get accused of "pumping"
They are more than likely to be given Fast track approval within the next 12-18 months (for the Keytruda combo) given the data we have seen to date, and having partners like Merck and MD Anderson on board, gets rid of the red tape you'd normally have as a small biotech.

See Pandion buyout where Merck made a cheeky offer of $65m. They ended up buying them for $1.9bn just a few months after their first offer. 4D has a much bigger pipeline.

https://www.fiercebiotech.com/biotech/pandion-s-secret-to-moving-a-65m-merck-offer-to-a-1-9b-done-deal-a-year-just-keep-saying-no

It's difficult to put an exact price on it, but it will br in the multi-billions. If you look at some of the NASDAQ acquisitions for company's barely in Phase 1 trials they have sold for $1.5-$2bn. Now add to the equation the fact that 4D are a in Phase 2/ Phase 3 with most of their pipeline, only 2-3 years away from bringing a drug to market, and most importantly improve the effectiveness substantially of a drug that bring in $14bn a year for Merck. What price do you put on that? $5bn, $10bn? Not only does it provide an additional revenue stream, but slso likely to boost rxisting sales of Keytruda. They paid $11.5bn ($180 a share)for Accrleron in September, and some of the shareholders there were against the deal as they felt they were being shortchanged.

Personally i don't see 4D staying around as an independant entity for much longer. The Keytruda trial is open label, so onnce they are satisfied with the data they see, Merck won't bat an eyelid taking us out. The last thing they want is to end up in a bidding war with their competitors like Pfizer, whom they can then charge a premium for the use of MRX0518 with Bavencio.

See this article from last month. Merck already own 5% of 4D, and are also in colloboration with MRX0518 and Keytruda. Below article sums up the insanse valuation these disruptives command.

https://www.ft.com/content/a9688ef3-42ad-4600-ac19-6b22783922c3

Yep he needs to join Stigologists 4D Telegram group, which he runs under the name of stocks. He will see what a nasty pump and dump operation his source is running. Another one tgat's sold out and now desperate to get back in.

Staylong you are quoting The Stigioligist on ADVFN, as if he some credible source. He is one the worst pump and dumpers out there. He was calling £10 at 4D by Q1 2021, £100 by end of 2021 and £1000 a share by 2026 lol. A far cry from £1.80 being quoted on here. Suggest you see yourself out this board, and post on the great shares you have invested in.

Good read about 4D's MicroX platform here, just shows how undervalued this share is.

https://www.nature.com/articles/d43747-020-01006-2

"4d is a very small investment for me and it’s the only share that I’m involved in that I took a real punt on. It might seem strange but I didn’t do any research on this one when I first invested"

Enough said. This muppet hasn't even researched the company, yet thinks he's qualified to distunguish between a pump and a correction. Pathetic attempts to deramp the SP.

Blah blah you two need to get a life and a room. Ignore the 2 muppets and conventrate on 4D

So it's ok for you to make commentary on price movements but yet when yet others do, they are frowned upon for not talking about the science and for being pump and dump traders?

Practise what you preach you lowlife. No more posts to this leech.

Sang's commebt at 62p on the 29th

"Seems like I was right albeit even I was being overly optimistic.this is in a death spiral and I really can't see anything lifting it. I am thinking wait til it drops a lot more before loading up again"

Obviously bitter the drop never came, and probably had to rebuy in higher than he sold. Jog on muppet